logo

Sarepta Therapeutics (SRPT)



Trade SRPT now with
  Date
  Headline
5/3/2018 4:05:32 PM Sarepta Therapeutics Q1 Loss/share $0.55 Vs. Profit $1.50 Year Ago
5/3/2018 4:05:11 PM Sarepta Therapeutics Enters Exclusive Partnership With Myonexus Therapeutics
4/3/2018 7:46:01 AM RBC Capital Markets Is Cutting Sarepta Therapeutics (SRPT) 4Q18 Estimate To -0.22 From -0.21
4/3/2018 7:45:38 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 2020 Estimate To 2.92 From 3.24
4/3/2018 7:45:28 AM RBC Capital Markets Is Cutting Sarepta Therapeutics (SRPT) 2019 Estimate To 1.15 From 1.26
4/3/2018 7:45:17 AM RBC Capital Markets Is Cutting Sarepta Therapeutics (SRPT) 2018 Estimate To -1.26 From -1.24
4/3/2018 7:44:24 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 4Q18 Rev. Estimate To 87.4 M From 88.0 M
4/3/2018 7:44:13 AM RBC Capital Markets Is Cutting Sarepta Therapeutics (SRPT) 3Q18 Rev. Estimate To 78.4 M From 78.8 M
4/3/2018 7:44:04 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 2Q18 Rev. Estimate To 72.2 M From 72.4 M
4/3/2018 7:43:54 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 1Q18 Rev. Estimate To 64.1 M From 64.2 M
4/3/2018 7:43:37 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 2020 Rev. Estimate To 768.0 M From 795.3 M
4/3/2018 7:43:26 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 2019 Rev. Estimate To 533.7 M From 542.2 M
4/3/2018 7:43:14 AM RBC Capital Markets Is Lowering Sarepta Therapeutics (SRPT) 2018 Rev. Estimate To 302.0 M From 303.5 M
3/20/2018 8:31:31 AM Sarepta Therapeutics Announces Launch Of Its Route 79, The Duchenne Scholarship Program